Synergy Pharmaceuticals
SGYP
SGYP was delisted on the 7th of March, 2019.
72 hedge funds and large institutions have $139M invested in Synergy Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 17 closing their positions.
260% more call options, than puts
Call options by funds: $824K | Put options by funds: $229K
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
1.68% less ownership
Funds ownership: 28.1% → 26.42% (-1.7%)
6% less funds holding
Funds holding: 77 → 72 (-5)
43% less capital inflows, than outflows
Capital inflows: $6.43M | Capital outflows: $11.3M
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Oxford Asset Management
Oxford,
United Kingdom
|
+$2.1M |
| 2 |
Renaissance Technologies
New York
|
+$912K |
| 3 |
Millennium Management
New York
|
+$617K |
| 4 |
State Street
Boston,
Massachusetts
|
+$417K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$381K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.5M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.75M |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$1.16M |
| 4 |
APU
Alpine Partners USVI
St. Thomas,
U.S. Virgin Islands
|
-$697K |
| 5 |
Morgan Stanley
New York
|
-$523K |
SGYP Hedge Fund Activity: Q4 2013 in Review
72 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q4 2013, worth a combined $139M — up 20% from $116M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SGYP and 7 opened new positions — a net loss of 10 holders — while 24 trimmed existing stakes and 25 added.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.1M. The largest seller was Fidelity Investments, cutting an estimated $3.5M.
- 72 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q4 2013, down from 77 in Q3 2013.
- Funds reported $139M of Synergy Pharmaceuticals stock for Q4 2013, up 20% quarter-over-quarter.
- 7 funds opened new Synergy Pharmaceuticals positions in Q4 2013 and 17 closed out, a net change of -10 holders.
- The largest Synergy Pharmaceuticals buyer in Q4 2013 was Oxford Asset Management, an estimated $2.1M added.
- The largest Synergy Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $3.5M sold.
Based on aggregated 13F filings for Q4 2013.